Z160 has blockbuster drug potential. If approved, we could see earnings of $1 - $4 BILLION annually. With 22 Million shares outstanding, that's earnings of $45 - $180 per share EVENTUALLY. With a modest P/E of, let's say 6, that brings us to $270 - $1080 per share. Sounds unbelievable until you do the math.
BUT, that most certainly will NOT happen in a year. Still talking 2 - 3 years minimum for NDA, and that's IF phase 2 and 3 go perfectly. Up to another year for an FDA approval (though Orphan drug designation should help us here), and then another 3 to 5 years to reach blockbuster sales with multiple indications. So could this be a huge payday? Yeah, it could. But I think we're 6 years away from maximum value, even though you could walk away with a decent gain within the next couple of months/years.
Of course, that also assumes ZLCS doesn't get bought out before maximum value can be reached. A buyout is highly probable imo, if phase II results are stellar. If borderline positive, a suitor might choose to partner instead. Of course, if results are firmly negative, then it's game over.
"RS came out of nowhere"? Why am I even wasting time reading this garbage. This stock is all about being patient and waiting for positive P II results. It's as simple as that. You committ a small portion of your portfolio to a few companies with potential upside like ZCLS and IMUC. My two plays. Not sure about 40 dollars per share but I think 18 is pretty realistic (again, only if positive P II results). Good luck to all longs (that's aren't looking to make $246 dollar profit and run :)